ArticleNature communications2024
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Article
- Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness.Pathogens (Basel, Switzerland) · 2026Review
- Prolonged persistence of tissue-resident memory cells in the upper airway following SARS-CoV-2 infection and vaccination.Clinical & translational immunology · 2026Article
- Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.Nature communications · 2025Article
- Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.Science advances · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Article
- Elucidating the molecular docking and binding dynamics of aptamers with spike proteins across SARS-CoV-2 variants of concern.Frontiers in microbiology · 2025Article
- Induction of tissue resident memory T cells by measles vaccine vector.Human vaccines & immunotherapeutics · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Yuexiu Zhang *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Michelle Chamblee *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Jiayu Xu *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Panke QuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Mohamed M ShamseldinDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-5324-1145
Sung J YooDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-0892-2718
Jack MisnyCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Ilada ThongpanCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Mahesh KcCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Jesse M HallDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.
Yash A GuptaDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.
John P EvansDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-8644-5825
Mijia LuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Chengjin YeTexas Biomedical Research Institute, San Antonio, TX, USA.ORCID 0000-0002-1934-9494
Cheng Chih HsuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Xueya LiangDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX, USA.ORCID 0000-0001-7084-0804
Jacob S YountDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-6128-4575
Prosper N BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-6857-9088
Shan-Lu LiuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-1620-3817
Purnima DubeyDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, USA.
Mark E PeeplesCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID 0000-0002-4582-317X
Jianrong LiDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA. li.926@osu.edu.ORCID 0000-0002-7130-1084
Funding
Technology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, Anna Karolina Palucka · 2019 to 2026
$23.1MRole of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and CoagulopathyP01AI175399 · NIAID · OHIO STATE UNIVERSITY · PI Amal O Amer, Estelle A Cormet-Boyaka · 2024 to 2026
$12.0MProject 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4MProject 3: Dr. LiP01AI112524 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E., RAMILO, OCTAVIO · 2015 to 2019
$6.8MMechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3MMessenger RNA Capping and Methylation in PneumovirusesR01AI090060 · NIAID · OHIO STATE UNIVERSITY · PI LI, JIANRONG · 2011 to 2023
$4.0MRespiratory Syncytial Virus Targeting of the Human Airway EpitheliumR01AI093848 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E. · 2012 to 2023
$3.8MHost Responses to the Pore-Forming Toxin Listeriolysin OR01AI157205 · NIAID · OHIO STATE UNIVERSITY · PI AMER, AMAL O, BOYAKA, PROSPER N · 2021 to 2025
$3.2MTargeting myeloid cells for regulation of alum-based immunityR01AI145144 · NIAID · OHIO STATE UNIVERSITY · PI BOYAKA, PROSPER N · 2020 to 2024
$3.1MMechanisms of lung and cardiac pathology in SARS-CoV-2 infectionsR01HL168501 · NHLBI · OHIO STATE UNIVERSITY · PI Amal O Amer, Jacob Yount · 2023 to 2026
$2.9MInterdisciplinary Program in Microbe-Host BiologyT32AI165391 · NIAID · OHIO STATE UNIVERSITY · PI RAJENDAR K DEORA, Daniel J Wozniak · 2022 to 2026
$1.5MRNA internal 2’-O methylation in SARS-CoV-2R21AI180667 · NIAID · OHIO STATE UNIVERSITY · PI LI, JIANRONG · 2024 to 2025
$453kDivision of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) U54CA260582NCI NIH HHS U54 CA260582NHLBI NIH HHS R01 HL168501NIAID NIH HHS P01 AI112524NIAID NIH HHS P01 AI175399NIAID NIH HHS R01 AI090060NIAID NIH HHS R01 AI093848NIAID NIH HHS R01 AI130110NIAID NIH HHS R01 AI145144NIAID NIH HHS R01 AI157205NIAID NIH HHS R21 AI180667NIAID NIH HHS T32 AI165391NIAID NIH HHS U19 AI142733U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32AI165391U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA260582U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI090060U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI093848U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI112524U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI145144U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI157205U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI175399U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI42733
Abstract
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1
Indexed as
Administration, IntranasalAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsCricetinaeFemaleHumansImmunoglobulin AImmunoglobulin GMeasles-Mumps-Rubella VaccineMeasles virusMesocricetusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GMeasles-Mumps-Rubella VaccineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.